
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc. is demonstrating significant progress in its drug development pipeline with key milestones expected in 2025 and 2026, particularly for its rhenium (186Re) obisbemeda treatment for CNS cancers. The company has recently secured an $18 million grant from the Cancer Prevention and Research Institute of Texas to advance its research on leptomeningeal metastases and has expanded the operational footprint of its CNSide Diagnostics platform to encompass 48 of 50 U.S. states, thus enhancing its revenue potential. The ongoing national payor coverage expansions and operational improvements within CNSide Diagnostics are likely to support enhanced adoption and increased test volumes, contributing to a positive long-term outlook for the company.
Bears say
Plus Therapeutics Inc. faces significant risks affecting its stock outlook, primarily due to the potential failure of its product candidates to demonstrate safety and efficacy in clinical trials. Additionally, the company's reliance on regulatory approval for commercial sale and suitable reimbursement presents further uncertainties that could impair financial performance. The competitive landscape and shifting macroeconomic factors further exacerbate these risks, contributing to a negative sentiment regarding the company's prospects.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares